Skeletal-related event rate and distribution by type
| Breast cancer | Prostate cancer | Other solid tumours | |
|---|---|---|---|
| SRE rate (per year) | |||
| Zoledronic acid | 0.631 | 0.947 | 0.936 |
| Denosumab (derived) | 0.486 | 0.777 | 0.796 |
| Denosumab treatment effect | |||
| Rate ratio first and subsequent SRE | 0.77 | 0.82 | 0.85 |
| SRE type distribution* (%) | |||
| Pathologic fracture | 58.2 | 26.8 | 31.4 |
| Radiation to bone | 35.4 | 66.1 | 57.5 |
| Surgery to bone | 4.7 | 1.5 | 6.2 |
| Spinal cord compression | 1.7 | 5.6 | 5.0 |
*Pooled across both treatment groups.
SRE, skeletal-related event.